MedTrace Logo

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

NCT02837328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-11-01

Study results available
· View outcomes & findings →

Summary

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

Conditions

  • Premature Atrial Contraction

Interventions

DRUG

Oral Magnesium Supplement

400 mg Magnesium Citrate 1x daily for 12 weeks

DRUG

Placebo

Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pamela L Lutsey, PhD · University of Minnesota

  • Alvaro Alonso, MD PhD · University of Minnesota

  • Lin Y Chen, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-09-15
Completion
2017-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837328 on ClinicalTrials.gov